225Ac-PSMA I&T的衰变子体转归及其对唾液腺和肾脏剂量的影响
该临床前研究在小鼠中比较了[225Ac]Ac-PSMA I&T与[177Lu]Lu-PSMA I&T的药代动力学,并评估了衰变子体重新分布对唾液腺和肾脏吸收剂量的影响。结果显示,[225Ac]Ac-PSMA I&T的靶向特征与[177Lu]类似,但其子体在唾液腺和肾脏的摄取高于平衡值,导致吸收剂量分别增加至2.5倍和1.3倍。
要点
- [225Ac]Ac-PSMA I&T的细胞结合与滞留特性与[177Lu]Lu-PSMA I&T相似。
- 肿瘤组织内221Fr和213Bi未见重新分布,子体被滞留于肿瘤。
- 游离子体在唾液腺和肾脏的摄取使吸收剂量分别增至2.5倍和1.3倍。
核心结论
- [225Ac]Ac-PSMA I&T的PSMA靶向特征和药代动力学与[177Lu]Lu-PSMA I&T相似。
- 其子体被滞留于肿瘤组织,而游离衰变产物在唾液腺和肾脏的摄取是225Ac治疗副作用高于177Lu放射性配体的额外原因。
研究设计与样本
- 临床前研究,在LNCaP和PC3 PIP细胞中进行体外实验。
- 在LNCaP荷瘤小鼠和健康小鼠中进行生物分布研究(注射后10分钟至7天)。
- 解剖后24小时通过定量221Fr(218 keV)和213Bi(440 keV)确定平衡摄取。
- 解剖后立即测量感兴趣组织(肾脏、唾液腺和肿瘤组织)直至达到平衡,以确定221Fr和213Bi的时间依赖性活度分布。
- 使用MIRDcalc计算吸收剂量,分别假设子体在首次衰变部位衰变与考虑游离子体重新分布。
主要发现
- [225Ac]Ac-PSMA I&T表现出与[177Lu]Lu-PSMA I&T相似的细胞结合特征和细胞滞留。
- 生物分布研究中,肿瘤组织内未测得221Fr和213Bi的重新分布。
- 与平衡时相比,死亡时肾脏中213Bi摄取更高(注射后10分钟和1小时均高2倍)。
- 与平衡时相比,死亡时唾液腺中213Bi摄取更高(注射后10分钟高1.7倍,1小时高8.5倍)。
- 假设221Fr摄取并原位形成213Bi,肾脏和唾液腺的吸收剂量分别增加至1.3倍和2.5倍。
临床怎么用
- 解释225Ac-PSMA治疗时唾液腺和肾脏副作用高于177Lu放射性配体的可能机制。
- 提示在225Ac-PSMA治疗剂量学评估中需考虑游离子体的重新分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
α-therapy with 225Ac-labeled radioligands targeting prostate-specific membrane antigen (PSMA) has emerged as a promising treatment option for advanced metastatic castration-resistant prostate cancer. Because of α-recoil, the progeny is released from the PSMA-targeted molecule and can undergo redistribution, contributing to off-target toxicity. Here, we report on biodistribution and dosimetry studies of [225Ac]Ac-PSMA I&T performed in mice to investigate the pharmacokinetics of the radioligand compared with unbound progeny. Moreover, the cellular uptake and externalization kinetics of [225Ac]Ac-PSMA I&T were compared with those of its 177Lu-labeled analog. Methods: In vitro studies were performed on LNCaP and PC3 PIP cells. Biodistribution studies (performed 10 min to 7 d after injection) were conducted in LNCaP tumor-bearing and healthy mice. Equilibrium uptake was determined 24 h after dissection by quantification of 221Fr (218 keV) and 213Bi (440 keV). Tissues of interest (kidneys, salivary glands, and tumor tissue) were measured immediately after dissection until reaching equilibrium to determine the time-dependent activity distribution of 221Fr and 213Bi. Absorbed doses were calculated using MIRDcalc, assuming decay of the progeny at the site of the first decay versus taking into account redistribution of unbound progeny. Results: [225Ac]Ac-PSMA I&T demonstrated cell-binding characteristics and cellular retention similar to those of [177Lu]Lu-PSMA I&T. In biodistribution studies, no redistribution of 221Fr and 213Bi was measured from tumor tissue. Higher uptake of 213Bi was found in the kidneys (2-fold higher at 10 min and at 1 h after injection) and salivary glands (1.7-fold and 8.5-fold higher at 10 min and 1 h after injection, respectively) at the time of death compared with equilibrium. This contribution increased the absorbed dose in the kidneys and salivary glands by a factor of 1.3 and 2.5, respectively, assuming uptake of 221Fr and in situ formation of 213Bi. Conclusion: The PSMA-targeting characteristics and pharmacokinetics of [225Ac]Ac-PSMA I&T are similar to those of [177Lu]Lu-PSMA I&T. The progeny of [225Ac]Ac-PSMA I&T is trapped in tumor tissue. Uptake of liberated decay products into the salivary glands and kidneys was identified as an additional factor explaining the increased side effects of 225Ac therapy compared with 177Lu-based radioligands.
引用
- Wurzer A, Sun B, Saleh S, et al. [225Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys. J Nucl Med. 2025. PMID: 41043997. doi:10.2967/jnumed.125.269744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。